Literature DB >> 17914739

Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.

Vikramjit S Kanwar1, Jessica Heath, Carolyn N Krasner, Jennifer M Pearce.   

Abstract

Advanced small cell carcinoma of the ovary (FIGO stage III or IV) is a rare and usually lethal tumor seen in adolescents and young women. In pediatric patients with advanced disease, there have been only two case reports of successful therapy, we report a third patient, diagnosed at 17 years of age, with an abdominal mass and metastatic disease to regional and distant lymph nodes, who was successfully treated with surgery and intensive multi-agent chemotherapy. Imatinib, thalidomide, and celecoxib were also administered for up to 24 months following initial chemotherapy. She remains in remission 3 years from diagnosis. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17914739     DOI: 10.1002/pbc.21333

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  5 in total

1.  Successful reproductive outcome following treatment of advanced small cell carcinoma of the ovary.

Authors:  N H Walker; M Sabanli; P H Sykes; P Russell; D Perez
Journal:  Gynecol Oncol Case Rep       Date:  2012-06-26

2.  Small Cell Ovarian Carcinomas - Characterisation of Two Rare Tumor Entities.

Authors:  K Münstedt; R Estel; T Dreyer; A Kurata; A Benz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-07       Impact factor: 2.915

3.  Ovarian small cell carcinoma complicated by carcinomatous meningitis.

Authors:  Naoko Kira; Noriyuki Takai; Terukazu Ishii; Kentaro Kai; Masakazu Nishida; Kaei Nasu; Kenji Kashima; Hisashi Narahara
Journal:  Rare Tumors       Date:  2012-05-17

4.  Small cell ovarian carcinoma: Long term survival in juvenile case with poor prognostic features.

Authors:  Lauren Stewart; Ruchi Garg; Rochelle Garcia; Elizabeth Swisher
Journal:  Gynecol Oncol Rep       Date:  2016-11-09

5.  Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.

Authors:  Clemens B Tempfer; Beate Schultheis; Ziad Hilal; Askin Dogan; Günther A Rezniczek
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.